Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of compounds in preparation of drugs for treating multi-drug resistant cancers

A multi-drug resistance and chemotherapy drug technology, applied in the direction of drug combination, anti-tumor drugs, pharmaceutical formulations, etc., can solve the problems of unsuccessful multi-drug resistant tumor reversal agents, etc.

Inactive Publication Date: 2020-02-14
MACAU UNIV OF SCI & TECH
View PDF4 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Clinical trials of the latest third-generation drugs are underway, but so far, there are no clinically successful reversal agents for multidrug-resistant tumors

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of compounds in preparation of drugs for treating multi-drug resistant cancers
  • Application of compounds in preparation of drugs for treating multi-drug resistant cancers
  • Application of compounds in preparation of drugs for treating multi-drug resistant cancers

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0115] Formula (II) compound cytotoxicity assay

[0116] The sulforhodamine B (SRB) assay is used to evaluate drug-induced cytotoxicity and cell proliferation. In short, before treatment, cells were collected, counted and planted on 96-well plates. Different concentrations of chemotherapeutics and Rg5 (concentrations 8, 4 and 2μM) were used to evaluate whether the combination can enhance the growth inhibitory effect of multidrug resistant cancer cells. Add 50 μL of culture medium containing 50% (W / V) TCA (10% final concentration of TCA), and incubate at 4° C. for 1 hour. The cells were washed five times with water, stained with 0.4% SRB in 1% V / V acetic acid solution (100 μl / well) for 10 minutes, then quickly washed with 1% acetic acid, and then dissolved with 200 μl of 10 mM Tris alkali solution (pH = 10.5 ). Evaluation of binding protein staining at a wavelength of 515nm ( Compound mode detection platform, molecular equipment, California, USA). By comparing the IC of chemo...

example 2

[0128] Effect of compound of formula (II) on apoptosis of multidrug resistant cancer cells

[0129] Cell cycle and apoptosis analysis

[0130] Flow cytometry is used to determine the effect of compounds of formula (II) on the cell cycle and apoptosis in multidrug resistance ABC transporter-dependent cancer cells. In the cell cycle experiment, A2780 / T cells were collected after 24 hours, 48 ​​hours or 72 hours of treatment, and washed twice with ice-cold PBS. Add 70% ice-cold ethanol at 4°C overnight or at -20°C for 2 hours to fix the cells. After washing again with PBS, the cells were stained with a staining solution for 30 minutes at room temperature. This staining solution contained PI (50 μg / ml) and RNase (200 μg / ml). Then pellet the cells, wash and resuspend in PBS, the final cell concentration is 1×10 6 / ml. The cell fluid was analyzed by the flow cytometer BDFACS Aria (San Jose, CA).

[0131] In the apoptosis analysis experiment, 1×106 treated cells were collected, washed a...

example 3

[0135] Synergistic effect of formula (II) compound and chemotherapeutics

[0136] The Chou-Talalay method (1997: Cambridge (UK): Biosoft.) was used to evaluate the synergistic therapeutic effect of Rg5 and docetaxel. This method is used to calculate the "combination index" (CI), which quantitatively describes the synergy (CI) 1). In short, the drug-resistant A2780 / T cells were exposed to the serially diluted Rg5 and docetaxel mixture solution for 48 hours. At several concentration points higher and lower than twice the IC50 series concentration, the method described above is used to evaluate the cytotoxicity of the combined application. By using CalcuSyn software v.2.1 (Bio-soft), the synergy is further refined into synergy (CI=0.3-0.7), strong synergy (CI=0.1-0.3) and very strong synergy (CI <0.1).

[0137] The degree of cell death reaches 50% (ED 50 ) And 90% (ED 90 ), the combination index (CI) values ​​of Rg5 and docetaxel are 0.23 and 0.05, as shown in Table 2. This indica...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides an application of a compound represented by a formula (I), and pharmaceutically acceptable salts or solvates of the compound in the preparation of drugs for treating multi-drugresistant cancers. A pharmaceutical composition comprises the compound represented by the formula (I) or pharmaceutically acceptable salts or solvates of the compound, and a chemotherapeutic drug picked from taxol, docetaxel, doxorubicin, 5-fluorouracil, and daunorubicin.

Description

Technical field [0001] The present invention relates to a method for treating multi-drug resistant cancer by administering saponins to a subject, especially but not limited to combined use with chemotherapeutics. The invention also relates to a combination of drugs for the treatment of multidrug resistant cancers. Background technique [0002] Cancer drug resistance is the main obstacle to the successful treatment of cancer with chemotherapeutics in clinical practice. Multidrug-resistance (MDR) is a common phenomenon in cancer cells. It is affected by multiple mechanisms, and cancer cells are less sensitive to chemotherapeutics. The mechanism specifically includes cancer cells efflux drugs more . Multidrug resistance can be congenital, so the inherent resistance is obvious at the beginning of treatment, or it may be the resistance that develops gradually after the beginning of treatment. Chemotherapy is currently the most effective and common method for the clinical treatment ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/704A61P35/00
CPCA61K31/704A61P35/00
Inventor 谢莹姜志宏
Owner MACAU UNIV OF SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com